Optimizing CLL Care: Navigating Treatment Modifications and Managing Adverse Events

The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.

The discussion covers proactive strategies and interventions for managing adverse events before dose modification and explores supportive care measures for chronic lymphocytic leukemia treatments, including variations based on specific Bruton tyrosine kinase inhibitors.

The discussion explores the frequency and impact of dose modifications due to adverse events, strategies for maintaining outcomes, monitoring protocols, and how these modifications affect long-term CLL therapy effectiveness and treatment decisions.

The discussion addresses when dose modifications are typically required in chronic lymphocytic leukemia treatment and identifies the most common reasons for these modifications.

The discussion addresses the economic impact of appropriate dose modifications on chronic lymphocytic leukemia management.

The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.

The discussion explores how Medicare's Part D smoothing program in 2025 might impact chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies and how pharmacists can help navigate this new program. The session concludes with closing remarks.